Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6–11 years): data from a French multicentre retrospective cohort in daily practice

Lasek, A.; Bellon, N.; Mallet, S.; Puzenat, E.; Bursztejn, A.‐C.; Abasq, C.; Mazereeuw‐Hautier, J.; Chiavérini, C.; Hubiche, T.; Raison Peyron, N.; Du‐Thanh, A.; Barbarot, S.; Aubert, H.; Reguiaï, Z.; Droitcourt, C.; Fievet, C.; Bellissen, A.; Bachelerie, M.; Nosbaum, Audrey; Leymarie, Alicia; Armingaud, P; Masson Regnault, M.; Mahé, E.

doi:10.1111/jdv.18450

Public

Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6–11 years): data from a French multicentre retrospective cohort in daily practice

Published in Journal of the European Academy of Dermatology and Venereology • Jul 20, 2022

Authors:

A. Lasek

N. Bellon

S. Mallet

Abstract

BACKGROUND: Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD). OBJECTIVE: The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice. METHODS: Patients aged 6-11, who had received a first dose o...

Subject

Medicine

Dupilumab

Atopic dermatitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!